NEURONOVA
NeuroNova is develops drug targets and candidates that demonstrate potential in the treatment of neurodegenerative diseases. Its products include sNN0029, a drug candidate for the treatment of amyotrophic lateral sclerosis; and sNN0031, a drug candidate for the treatment of moderate to severe stage Parkinson’s disease that is designed to act on neural stem and progenitor cells in the brain.
NEURONOVA
Industry:
Biotechnology Medical Pharmaceutical
Founded:
1998-01-01
Address:
Stockholm, Stockholms Lan, Sweden
Country:
Sweden
Website Url:
http://www.neuronova.com
Status:
Active
Contact:
+46 87 86 09 00
